Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135663 | 0.86 | RXFP1 (0.65) | FLT3MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL134640 | 0.82 | MEN1 (0.67) | FLT3MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL4060800 | 0.82 | TDP1 (0.71) | FLT3MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL31502646 | 0.81 | MAPT (0.65) | FLT3MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL4380481 | 0.78 | MAPT (0.66) | FLT3MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL5460296 | 0.75 | FLT3 (0.80) | FLT3MAPTTP53THRBTDP1 | |
| SCHEMBL20128476 | 0.75 | ALDH1A1 (0.66) | FLT3MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL134601 | 0.73 | TDP1 (0.69) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL22543215 | 0.73 | ALDH1A1 (0.62) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL135664 | 0.72 | ALDH1A1 (0.73) | FLT3MAPTALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | FLT3 2523/4885MAPT 2061/4885ALDH1A1 1925/4885 |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | FLT3 2523/4885MAPT 2061/4885ALDH1A1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.